NYSE:HAE - Haemonetics Stock Price, Forecast & News

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

Haemonetics announced that its Board of Directors has authorized a share buyback plan on Tuesday, February 6th 2018, which allows the company to repurchase $260,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to reacquire shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company's management believes its shares are undervalued.

Haemonetics Co. (NYSE:HAE) posted its quarterly earnings data on Friday, November, 1st. The medical instruments supplier reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.15. The medical instruments supplier had revenue of $252.57 million for the quarter, compared to analysts' expectations of $249.77 million. Haemonetics had a return on equity of 24.59% and a net margin of 6.90%. View Haemonetics' Earnings History.

Haemonetics is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Haemonetics.

Haemonetics updated its FY20 earnings guidance on Friday, November, 1st. The company provided EPS guidance of $3.10-3.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.09. The company issued revenue guidance of +3-5% yr/yr to ~$996.6 million to $1.02 billion, compared to the consensus revenue estimate of $1.01 billion.

5 equities research analysts have issued 1 year price objectives for Haemonetics' shares. Their forecasts range from $140.00 to $150.00. On average, they expect Haemonetics' share price to reach $144.80 in the next year. This suggests a possible upside of 22.5% from the stock's current price. View Analyst Price Targets for Haemonetics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Haemonetics.

Media headlines about HAE stock have trended somewhat negative this week, according to InfoTrie. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Haemonetics earned a news sentiment score of -1.7 on InfoTrie's scale. They also gave media headlines about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Haemonetics.

Haemonetics saw a drop in short interest in the month of October. As of October 31st, there was short interest totalling 717,000 shares, a drop of 13.3% from the September 30th total of 826,800 shares. Based on an average trading volume of 337,600 shares, the short-interest ratio is currently 2.1 days. Approximately 1.4% of the company's shares are sold short. View Haemonetics' Current Options Chain.

Some companies that are related to Haemonetics include Align Technology (ALGN), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), West Pharmaceutical Services (WST), ICU Medical (ICUI), Neogen (NEOG), Quidel (QDEL), STAAR Surgical (STAA), Merit Medical Systems (MMSI), Atrion (ATRI), Anika Therapeutics (ANIK), Antares Pharma (ATRS), Cerus (CERS), OraSure Technologies (OSUR) and Utah Medical Products (UTMD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include Endologix (ELGX), Align Technology (ALGN), Apache (APA), Chipotle Mexican Grill (CMG), Zoetis (ZTS), Micron Technology (MU), Aegean Marine Petroleum Network (ANW), CA (CA), NVIDIA (NVDA) and Nexstar Media Group (NXST).

Haemonetics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include State Street Corp (3.32%), Eagle Asset Management Inc. (1.17%), Fisher Asset Management LLC (0.47%), Voya Investment Management LLC (0.46%), Russell Investments Group Ltd. (0.45%) and Emerald Advisers LLC (0.40%). Company insiders that own Haemonetics stock include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Mark W Kroll, Michelle L Basil, Neil Mr Ryding, Pedro P Granadillo, Richard J Meelia, Ronald G Gelbman, Said Bolorforosh and William P Mr Burke. View Institutional Ownership Trends for Haemonetics.

HAE stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Picton Mahoney Asset Management, Morse Asset Management Inc, Rhumbline Advisers, Public Employees Retirement System of Ohio, Barclays PLC, Voya Investment Management LLC and Systematic Financial Management LP. Company insiders that have sold Haemonetics company stock in the last year include Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Michelle L Basil, Richard J Meelia, Ronald G Gelbman, Said Bolorforosh and William P Mr Burke. View Insider Buying and Selling for Haemonetics.

HAE stock was purchased by a variety of institutional investors in the last quarter, including Cookson Peirce & Co. Inc., Public Employees Retirement Association of Colorado, Lisanti Capital Growth LLC, Millennium Management LLC, State of New Jersey Common Pension Fund D, California Public Employees Retirement System, First Trust Advisors LP and Catalyst Capital Advisors LLC. View Insider Buying and Selling for Haemonetics.

Shares of HAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of HAE stock can currently be purchased for approximately $118.18.

Haemonetics has a market capitalization of $5.99 billion and generates $967.58 million in revenue each year. The medical instruments supplier earns $55.02 million in net income (profit) each year or $2.39 on an earnings per share basis. Haemonetics employs 3,216 workers across the globe.View Additional Information About Haemonetics.

The official website for Haemonetics is http://www.haemonetics.com/.

Haemonetics' mailing address is 400 WOOD RD, BRAINTREE MA, 02184. The medical instruments supplier can be reached via phone at 781-848-7100 or via email at [email protected]